Ahmet Dirican: Apixaban vs Rivaroxaban in Acute VTE
Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X about a recent article by Lana A. Castellucci et al, published in The New England Journal of Medicine:
”New NEJM trial: Apixaban vs Rivaroxaban in acute VTE
Clinically relevant bleeding:
Apixaban 3.3%
Rivaroxaban 7.1%
RR 0.46
- Similar efficacy for recurrent VTE
- Significantly lower bleeding with apixaban
However, an important limitation: Cancer-associated thrombosis patients were excluded from the trial.
So there is no direct evidence in oncology patients. Still, in daily oncology practice — especially in patients with higher bleeding risk — this signal may be worth keeping in mind when choosing between DOACs.”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger
Read the Full Article on The New England Journal of Medicine
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 13, 2026, 16:47Sinju Thomas: Combined Red Cell and Plasma Exchange for Severe FES in Sickle Cell Disease
-
Mar 13, 2026, 16:44Michael Makris: Lower Bleeding Risk With Apixaban vs Rivaroxaban in Acute Venous Thrombosis
-
Mar 13, 2026, 16:36Muhammad Bilal: Principles and Clinical Uses of the Coombs Test
-
Mar 13, 2026, 16:27Nikhil Ganjoo: Early Detection of Rare Diseases Through Newborn Genome Sequencing
-
Mar 13, 2026, 16:18Tareq Abadl: Anemia of Inflammation – Hepcidin Regulation of Iron
-
Mar 13, 2026, 16:15New Evidence From the COBRRA Trial in Acute VTE – THANZ
-
Mar 13, 2026, 16:09Wolfgang Miesbach: Brussels Will Be the Perfect Stage for EAHAD 2027
-
Mar 13, 2026, 15:59Nicola Pozzi: A Brand-New Mechanism to Reduce Thrombosis Without Increasing Bleeding Risk
-
Mar 13, 2026, 15:47Heghine Khachatryan: Real-World Data on DOAC Use in Pediatric Oncology